These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21946305)

  • 1. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 3. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
    Minuk A; Belliveau MJ; Almeida DR; Dorrepaal SJ; Gale JS
    JAMA Ophthalmol; 2013 Jun; 131(6):802-4. PubMed ID: 23599188
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM
    N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
    Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B
    Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856
    [No Abstract]   [Full Text] [Related]  

  • 15. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
    van Rossum JA; Looysen EE; Daniels JM; Killestein J
    Mult Scler; 2014 Nov; 20(13):1792-3. PubMed ID: 24866203
    [No Abstract]   [Full Text] [Related]  

  • 17. Sudden unexpected death on fingolimod.
    Lindsey JW; Haden-Pinneri K; Memon NB; Buja LM
    Mult Scler; 2012 Oct; 18(10):1507-8. PubMed ID: 22300970
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of fingolimod-associated macular edema.
    Chui J; Herkes GK; Chang A
    JAMA Ophthalmol; 2013 May; 131(5):694-6. PubMed ID: 23538612
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.